Search for a trial

A modular, first time in human, open label, multiple dose, accelerated escalation with cohort expansion study of the safety and pharmacokinetics of intravenous infusion of CP-506, a tumor agnostic Hypoxia Activated Prodrug in patients with HRD/FAD solid tumors or tumor types with high incidence of HRD/FAD in monotherapy or in combination with carboplatin or patients with solid tumor and oligoprogressive disease receiving immune checkpoint inhibitors (ICI): a phase I-IIa

This study has been transitioned to CTIS with ID 2023-506818-45-00 check the CTIS register for the current data. The study*s primary objective is to assess the safety and tolerability of CP-506 alone or in combination therapy. The 3 different…